Description:
Marizomib (NPI-0052, salinosporide A) (news articles ^[1]) is a novel proteasome inhibitor that suppresses tumor growth by inhibiting the enzymes that break down important proteins in cancerous cells.  Marizomib may be used as an alternative treatment to Velcade ^[2] (bortezomib), the first approved proteasome inhibitor, because it has shown significant activity against multiple myeloma that was previously resistant to Velcade.  Marizomib is often administered orally or intravenously as either a single agent or in combination with other anti-cancer agents.

Clinical Trials:
For a list of clinical trials studying marizomib for the treatment of multiple myeloma, see ClinicalTrials.gov ^[3].